Professional Documents
Culture Documents
Department
of
Microbiology,
Science, Achievers University, Owo ,Ondo state, Nigeria Tel No-08063813636, 08056096672,08062484836 E-mail-osuntokun4m@yahoo.com, osuntokun4m@gmail.com,ojorufus2011@yahoo.com ABSTRACT This article presents a comprehensive review of the Breast Cancer literature examining epidemiology, diagnosis, pathology, benignbreast disease, breast carcinoma in situ syndromes, staging, and post-treatment surveillance among many topics. Breast cancer remains the most commonly occurring cancer in women in Ondo state using Owo local government as a case study.. Breast cancer detection, treatment, and prevention are prominent issues in public health and medical practice. Background information on developments in these arenas is provided so that Medical Microbiologist And Economics alike can continue to update their approach to the assessment of breast cancer risk to enhance productivity in the local government and Nigeria as whole.
Introduction
Breast cancer was the form of cancer most often described in ancient documents. Because autopsies were rare, cancers of the internal organs were essentially invisible to ancient medicine. Breast cancer, however, could be felt through the skin, and in its advanced state often developed into fungating lesions: the tumor would become necrotic (die from the inside, causing the tumor to appear to break up) and ulcerate through the skin, weeping fetid, dark fluid.19 The oldest description of cancer was discovered in Egypt and dates back to approximately 1600 BC. For centuries, physicians described similar cases in their practices, with the same conclusion. Ancient medicine, from the time of the Greeks through the 17th century, was based on humoralism, and thus believed that breast cancer was generally caused by imbalances in the fundamental fluids that controlled the body, especially an excess of black bile 18 Alternatively, patients often saw it as divine punishment, in the 18th century, a wide variety of medical explanations were proposed, including a lack of sexual activity, too much sexual activity, physical injuries to the breast, curdled breast milk, and various forms of lymphatic blockages, either internal or due to restrictive clothing. In the 19th century, the Scottish surgeon John Rodman said that fear of cancer caused cancer, and that this anxiety, learned by example from the mother, accounted for breast cancer's tendency to run in families.17 Although breast cancer was known in ancient times, it was uncommon until the 19th century, when improvements in sanitation and control of deadly infectious diseases resulted in dramatic increases in lifespan. Previously, most women had died too young to have developed breast cancer. Additionally, early and frequent childbearing and breastfeeding probably reduced the rate of breast cancer development in those women who did survive to middle age
Mastectomy for breast cancer was performed at least as early as AD 548, when it was proposed by the court physician Aetios of Amida to Theodora. It was not until doctors achieved greater understanding of the circulatory system in the 17th century that they could link breast cancer's spread to the lymph nodes in the armpit. The French surgeon Jean Louis Petit(16741750) and later the Scottish surgeon Benjamin Bell (17491806) were the first to remove the lymph nodes, breast tissue, and underlying chest muscle.44
organs. Nearly all women with cancer at this stage can be cured. Mammograms find many cases of DCIS. 2.Invasive (or infiltrating) ductal carcinoma (IDC): This is the most common breast cancer. It starts in a milk passage (a duct), breaks through the wall of the duct, and invades the tissue of the breast. From there it may be able to spread (metastasize) to other parts of the body. It accounts for about 8 out of 10 invasive breast cancers. 3.Invasive (infiltrating) lobular carcinoma (ILC): This cancer starts in the milk glands (the lobules) and then spreads through the wall of the lobules. It can then spread(metastasize) to other parts of the body. About 1 in 10 invasive breast cancers are of this type. 4.Inflammatory breast cancer (IBC): This uncommon type of invasive breast cancer accounts for about 1% to 3% of all breast cancers. Usually there is no single lump or tumor. Instead, IBC makes the skin of the breast look red and feel warm. It also may make the skin look thick and pitted, something like an orange peel. The breast may get bigger, hard, tender, or itchy. [12] PATHOLOGY OF BREAST CANCER Ninety-five percent of breast cancers are carcinomas, ie, they arise from breast epithelial elements. Breast cancers are divided into 2 major types, in situ carcinomas and invasive (or infiltrating) carcinomas. The in situ carcinomas may arise in either ductal or lobular epithelium, but remain confined there, with no invasion of the underlying basement membrane that would constitute extension beyond epithelial boundaries. As would be expected with such localized and confined malignancy, there is negligible potential for metastases. When there is extension of the ductal or lobular malignancy beyond the basement membrane that constitutes the epithelial border, then the malignancy is considered invasive (or infiltrating) ductal or lobular carcinoma. The potential for metastases and ultimately death occurs in invasive disease.
8.A marble-like hardened area under the skin12 These changes may be found when performing monthly breast self-exams. By performing breast self-exams, you can become familiar with the normal monthly changes in your breasts. Breast self-examination should be performed at the same time each month, three to five days after your menstrual period ends. If you have stopped menstruating, perform the exam on the same day of each month.
The tumor is less than an inch across but has spread to the underarm lymph nodes (IIA); or
The tumor is between 1 and 2 inches (with or without spread to the lymph nodes); or
The tumor is larger than 2 inches and has not spread to the lymph nodes under the arm (both IIB).
Advanced breast cancer (metastatic) results after cancer cells spread to the lymph nodes and to other parts of the body.
Stage III breast cancer is also called "locally advanced breast cancer." The tumor is larger than 2 inches and has spread to the lymph nodes under the arm, or a tumor that is any size with cancerous lymph nodes that adhere to one another or to surrounding tissue (IIIA). Stage IIIB breast cancer is a tumor of any size that has spread to the skin, chest wall, or internal mammary lymph nodes (located beneath the breast and inside the chest). Stage IV breast cancer is defined as a tumor, regardless of size, that has spread to areas away from the breast, such as bones, lungs, or liver.
Radial scars are benign breast lesions of uncertain pathogenesis, which are usually discovered incidentally when a breast mass is removed for other reasons. Radial scars are characterized by a fibroelastic core from which ducts and lobules radiate.11 Atypical hyperplasia of either ductal or lobular cells, where the cells are uniform but have lost their apical-basal cellular orientation, confers a 4-fold increased risk unless there is also a family history of 1 or more first-degree relatives with breast cancer, where the risk increases to 6-foldsine kinase activity. Women with atypical hyperplasia with over-expression of HER-2/neu have a greater than 7-fold increased risk of developing invasive breast carcinoma, as compared with women with non-proliferative benign breast lesions and no evidence of HER-2/neu amplification,13 Nipple discharge is often of concern to women and their physicians as a sign of malignancy, but the reality is that non-bloody nipple discharge and bilateral nipple discharge are usually of benign causation. Women with papillomas often have bloody discharge. Nipple discharge is uncommon in invasive breast cancer and if present is invariably unilateral and is usually associated with a palpable mass.8 Breast pain is an uncommon presentation of breast cancer. In a study of 987 women referred for breast imaging because of breast pain alone, only 4 women (0.4%) were found to have invasive breast cancer, a number that was not different from a control asymptomatic group.9
Solitary papillomas are also benign lesions conferring no increased risk of future malignancy, despite the fact that they are often7with sanguineous or serosanguineous nipple discharge. Fibrocystic-change (cysts and/or fibrous tissue without symptoms) or fibrocystic disease (fibrocystic changes occurring in conjunction with pain, nipple discharge, or a degree of lumpiness sufficient to cause suspicion of cancer) does not carry increased risk for cancer (other than the potential for missing a malignant mass). Some clinicians differentiate fibrocystic change or disease into those of hyperplasia, adenosis, and cystic change because of their differentiation into age distributions. Hyperplasia characteristically occurs in women in their 20s, often with upper outer quadrant breast pain and an indurated axillary tail, as a result of stromal proliferation. Women in their 30s present with solitary or multiple breast nodules 210 mm in size, as a result of proliferation of glandular cells. Women in their 30s and 40s present with solitary or multiple cysts. Acute enlargement of cysts may cause pain, and because breast ducts are usually patent, nipple discharge is common with the discharge varying in color from pale green to brown.28
2.Mammography: An X-ray test of the breast can give important information about a breast lump. 3.Digital mammography: A technique in which an X-ray image of the breast is digitally recorded into a computer rather than on a film. This may be better for women with dense breasts. 4.Ultrasonography: This test uses sound waves to detect the character of a breast lump -- whether it is a fluid-filled cyst (not cancerous) or a solid mass (which may or may not be cancerous). This may be performed along with the mammogram. 15 Based on the results of these tests, your doctor may or may not request a biopsy test to get a sample of the breast mass cells or tissue. Biopsies are performed using surgery or needles. 1.After the sample is removed, it is sent to a lab for testing. A pathologist -- a doctor who specializes in diagnosing abnormal tissue changes -- views the sample under a microscope and looks for abnormal cell shapes or growth patterns. When cancer is present, the pathologist can tell what kind of cancer it is (ductal or lobular carcinoma) and whether it has spread beyond the ducts or lobules (invasive). 2.Laboratory tests, such as hormone receptor tests (estrogen and progesterone) and human epidermal growth factor receptor (HER2/neu), can show whether hormones or growth factors are helping the cancer grow. If the test results show that they are (a positive test), the cancer is likely to respond to hormonal treatment or antibody treatment.10 These therapies deprive the cancer of the estrogen hormone or use a monoclonal antibody known as herceptin to treat the cancer.
3.Breast cancer diagnosis and treatment are best accomplished by a team of experts working together with the patient. Each patient needs to evaluate the advantages and limitations of each type of treatment and work with her team of physicians to develop the best approach.
reduce the chance of the cancer traveling to a location outside of the breast. Treatment generally follows within a few weeks after the diagnosis. The type of treatment recommended will depend on the size and location of the tumor in the breast, the results of lab tests done on the cancer cells, and the stage, or extent, of the disease. Your doctor will usually consider your age and general health as well as your feelings about the treatment options. Breast cancer treatments are local or systemic. Local treatments are used to remove, destroy, or control the cancer cells in a specific area, such as the breast. Surgery and radiation treatment are local treatments. Systemic treatments are used to destroy or control cancer cells all over the body. Chemotherapy and hormone therapy are systemic treatments. A patient may have just one form of treatment or a combination, depending on her needs. Surgery: Breast conservation surgery involves removing the cancerous portion of the breast and an area of normal tissue surrounding the cancer, while striving to preserve the normal appearance of the breast. This procedure has often been called a lumpectomy, which is a partial mastectomy. Some of the lymph nodes under the arm are also removed. Usually, six weeks of radiation therapy is then used to treat the remaining breast tissue. Most women who have a small, early-stage tumor are excellent candidates for this approach.16
or anastrozole (ARIMIDEX) or possibly chemotherapy. These treatments are used in addition to, but not in place of, local breast cancer treatment with surgery and/or radiation therapy.19
or not you want to read about survival rates is up to you. If you decide that you do not want to read about them, skip to the next section. The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is found. Of course, many people live much longer than 5 years. Also, people with cancer can die from other things, and these numbers do not take into account the fact that some of the deaths are from causes other than breast cancer. These numbers are based on women treated a number of years ago. Because we now find more cancers early and use newer, better treatments, the survival rates are getting better all the time. Risk factors for breast cancer 1. Lifestyle 1.Smoking- tobacco appears to increase the risk of breast cancer with the greater the amount of smoked and the earlier in life smoking began the higher the risk. [23] In those who are long term smokers the risk is increased 35% to 50%. 14 A lack of physical activity has been linked to ~10% of cases.22 2.Breast feeding. -The association between breast feeding and breast cancer has not been clearly determined with some studies finding support for an association and others not. 3.Abortion-breast cancer hypothesis -In the 1980s the abortionbreast cancer hypothesis posited that induced abortion increased the risk of developing breast cancer.[26 4.Miscarriages nor abortions- This hypothesis has been the subject of extensive scientific inquiry which has concluded that neither miscarriages nor abortions are associated.[6] 5Oral contraceptives .-There may be an association between oral contraceptives and the development of premenopausal breast cancer.26 6.Not breastfeeding: Some studies have shown that breastfeeding slightly lowers breast
cancer risk, especially if the breastfeeding lasts 1 to 2 years. This could be because breastfeeding lowers a womans total number of menstrual periods, as does pregnancy. But this has been hard to study because, in countries such as the United States, breastfeeding for this long is uncommon.29 7.Being overweight or obese: Being overweight or obese after menopause (or because of weight gain that took place as an adult) is linked to a higher risk of breast cancer. But the link between weight and breast cancer risk is complex. The risk seems to be higher if theextra fat is around the waist.
8.Lack of exercise: Studies show that exercise reduces breast cancer risk. The only question is how much exercise is needed. One study found that as little as 1 hour and 15 minutes to 2 hours of brisk walking per week reduced the risk by 18%. Walking 10 hours a week reduced the risk a little more.
womans risk. Its important to note that most (over 85%) women who get breast cancer do not have a family history of this disease, so not having a relative with breast cancer doesnt mean you wont get it. 5.Personal history of breast cancer: A woman with cancer in one breast has a greater chance of getting a new cancer in the other breast or in another part of the same breast. This is different from a return of the first cancer (called a recurrence). 6.Race: Overall, white women are slightly more likely to get breast cancer than AfricanAmerican women. African American women, though, are more likely to die of breast cancer. And in women under 45 years of age, breast cancer is more common in African American women. Asian, Hispanic, and Native-American women have a lower risk of getting and dying from breast cancer. 7.Dense breast tissue: Dense breast tissue means there is more gland tissue and less fatty tissue. Women with denser breast tissue have a higher risk of breast cancer. Dense breast tissue can also make it harder for doctors to spot problems on mammograms. 8.Certain benign (not cancer) breast problems: Women who have certain benign breast changes may have an increased risk of breast cancer. Some of these are more closely linked to breast cancer risk than others. For more details about these, see our document, 9.Non-cancerous Breast Conditions. Lobular carcinoma in situ: In this condition, cells that look like cancer cells are in the milk-making glands (lobules), but they do not grow through the wall of the lobules and cannot spread to other parts of the body. It is not a true cancer or pre-cancer, but having LCIS increases a woman's risk of getting cancer in either breast later. For this reason, it's important that women with LCIS make sure they have regular mammograms and doctor visits. Women with lobular carcinoma in situ (LCIS) have a 7 to 11 times greater risk of developing cancer in either breast.
10.Menstrual periods: Women who began having periods early (before age 12) or who went through the change of life (menopause) after the age of 55 have a slightly increased risk of breast cancer. The increase in risk may be due to a longer lifetime exposure to the hormones estrogen and progesterone. 11.Breast radiation early in life: Women who have had radiation treatment to the chest area (as treatment for another cancer) earlier in life have a greatly increased risk of breast cancer. The risk varies with the patients age when she had radiation. The risk from chest radiation is highest if the radiation were given during the teens, when the breasts were still developing. Radiation treatment after age 40 does not seem to increase breast cancer risk. 12.Treatment with DES: In the past, some pregnant women were given the drug DES (diethylstilbestrol) because it was thought to lower their chances of losing the baby (miscarriage). Studies have shown that these women have a slightly increased risk of getting breast cancer. The effect on the children exposed in the womb is less clear, but they may also have a slightly higher risk of breast cancer
treated with drugs that either block the receptors, e.g. tamoxifen (Nolvadex), or alternatively block the production of estrogen with an aromatase inhibitor, e.g. anastrozole (Arimidex)34 or letrozole(Femara). Aromatase inhibitors, however, are only suitable for post-menopausal patients. This is because the active aromatase in postmenopausal women is different from the prevalent form in premenopausal women, and therefore these agents are ineffective in inhibiting the predominant aromatase of premenopausal women Chemotherapy Predominately used for stage 24 disease, being particularly beneficial in estrogen receptor-negative (ER-) disease. They are given in combinations, usually for 36 months. One of the most common treatments is cyclophosphamide plus doxorubicin (Adriamycin), known as AC. Most chemotherapy medications work by destroying fastgrowing and/or fast-replicating cancer cells either by causing DNA damage upon replication or other mechanisms; these drugs also damage fast-growing normal cells where they cause serious side effects. Damage to the heart muscle is the most dangerous complication of doxorubicin. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. Another common treatment, which produces equivalent results, is cyclophosphamide, methotrexate, and fluorouracil (CMF). (Chemotherapy can literally refer to any drug, but it is usually used to refer to traditional non-hormone treatments for cancer.15
Radiation
Radiation is given after surgery to the region of the tumor bed and regional lymph nodes, to destroy microscopic tumor cells that may have escaped surgery. It may also have a beneficial effect on tumor microenvironment.38
Radiation therapy can be delivered as external beam radiotherapyor as brachytherapy (internal radiotherapy). Conventionally radiotherapy is given after the operation for breast cancer. Radiation can also be given at the time of operation on the breast cancerintra operatively. The largest randomized trial to test this approach was the TAR-GIT-A Trial.21 Radiation which found that targeted intraoperative radiotherapy was equally effective at 4-years as the usual several weeks' of whole breast external beam radiotherapy. Radiation can reduce the risk of recurrence by 5066% (1/2 2/3 reduction of risk) when delivered in the correct dose and is considered essential when breast cancer is treated by removing only the lump (Lumpectomy or Wide local excision). Can breast cancer be prevented? There is no sure way to prevent breast cancer. But there are things all women can do that might reduce their risk and help increase the odds that if cancer does occur, it is found at an early, more treatable stage. Lowering your risk: You can lower your risk of breast cancer by changing those risk factors that are under your control. Body weight, physical activity, and diet have all been linked to breast cancer, so these might be areas where you can take action. At this time, the best advice about diet and activity to possibly reduce the risk of breast cancer is to: 1.Get regular physical activity. 2.Reduce your lifetime weight gain by eating fewer calories and getting regular exercise. 3.Avoid or limit your alcohol intake. To find out more, see our document, American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention. Women who choose to breastfeed for at least several months may also reduce their breast cancer risk. Not using hormone therapy after menopause can also help you avoid
raising your risk. It's not clear at this time whether chemicals that have estrogen-like properties (like those found in some plastic bottles or certain cosmetics and personal care products) increase breast cancer risk. If there is an increased risk, it is likely to be very small. Still, women who are concerned may choose to avoid products that contain these substances when they can3. Finding breast cancer early: It is also important for women to follow the American Cancer Societys guidelines for finding breast cancer early. Society and culture belief/Effect of breast cancer Before the 20th century, breast cancer was feared and discussed in hushed tones, as if it were shameful. As little could be safely done with primitive surgical techniques, women tended to suffer silently rather than seeking care. When surgery advanced, and long-term survival rates improved, women began raising awareness of the disease and the possibility of successful treatment. The "Women's Field Army", run by the American Society for the Control of Cancer (later the American Cancer Society) during the 1930s and 1940s was one of the first organized campaigns. In 1952, the first peer-to-peer support group, called "Reach to Recovery", began providing post-mastectomy, inhospital visits from women who had survived breast cancer.43 The breast cancer movement of the 1980s and 1990s developed out of the larger feminist movements and women's health movement of the 20th century. This series of political and educational campaigns, partly inspired by the politically and socially effective AIDS awareness campaigns, resulted in the widespread acceptance of second opinions before surgery, less invasive surgical procedures, support groups, and other advances in patient care
Breast cancer culture, or pink ribbon culture, is the set of activities, attitudes, and values that surround and shape breast cancer in public. The dominant values are selflessness, cheerfulness, unity, and optimism. Appearing to have suffered bravely is the passport into the culture. The woman with breast cancer is given a cultural template that constrains her emotional and social responses into a socially acceptable discourse: She is to use the emotional trauma of being diagnosed with breast cancer and the suffering of extended treatment to transform herself into a stronger, happier and more sensitive person who is grateful for the opportunity to become a better person. Breast cancer thereby becomes a rite of passage rather than a disease.4 To fit into this mold, the woman with breast cancer needs to normalize and feminize her appearance, and minimize the disruption that her health issues cause anyone else. Anger, sadness and negativity must be silenced. he primary purposes or goals of breast cancer culture are to maintain breast cancer's dominance as the preminent women's health issue, to promote the appearance that society is "doing something" effective about breast cancer, and to sustain and expand the social, political, and financial power of breast cancer activists.43
Reference
1.Albertini J, Lyman G, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:18181822. 2. American Cancer Society (2007). "Cancer Facts & Figures 2007" (PDF). Archived from the original on 10 April 2007. Retrieved 2007-04-26
3. Alfredo Morabia (2004). A History of Epidemiologic Methods and Concepts Boston: Birkhauser. pp. 301302. ISBN 3-7643-6818-7. Retrieved 2007-12-31. 4. . American Cancer Society (2005). "Breast Cancer Facts & Figures 20052006" (PDF). Archived from the original on 13 June 2007. Retrieved 2007-04-26. 5, Bassett L, Winchester D, Caplan R, et al. Stereotactic core needle biopsy of the breast: A report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. CA Cancer J Clin. 1997:47:171. 6. Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G; Collaborative Group on Hormonal Factors in Breast, Cancer (27 March 2004). "Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries.". Lancet 363 (9414): 1007 16. Doi :10.1016/S0140- 6736(04)15835-2. PMID 15051280. 7. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146151. 8. .Donegan W. Diagnosis. In: Donegan W, Spratt J,eds. Cancer of the Breast. Philadelphia, PA: WB Saunders; 1995:157. 9 Duijan L, Guit G, Hendriks J, et al. Value of breast imaging in women with painful breasts: observational follow-up study. BMJ. 1998:317:1492. 10. Donegan W. Evaluation of a palpable breast mass. N Engl J Med. 1992;327:937 942. 11. Fiorica J. Fibrocystic changes. Obstet Gynecol Clin North Am. 1994:21:445. 12. . Jacobs TW, Byrne C, Colditz G, et al. Radical scars in benign breast biopsy specimens and the risk of breast cancer. N Engl J Med. 1999;340:430.
13. Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000;18:267. 14. Johnson KC, Miller, AB, Collishaw, NE, Palmer, JR, Hammond, SK, Salmon, AG, Cantor, KP, Miller, MD, Boyd, NF, Millar, J, Turcotte, F (Jan 2011). "Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009).". Tobacco control 20 (1): e2. doi:10.1136/tc.2010.035931. PMID 21148114. 15.Jahanzeb M (August 2008). "Adjuvant trastuzumab therapy for HER2-positive breast cancer". Clin. Breast Cancer 8 (4): 32433. doi:10.3816/CBC.2008.n.037. PMID 18757259. 16. .Harris J, Lippman M, Veronesi U, et al. Breast Cancer(3 parts). N Engl J Med. 1992:327:319479.2. From the Centers for Disease Control and Prevention: Breast Cancer Incidence and MortalityUnited States 1992. JAMA. 1996;276:1293. 17. History of Breast Cancer". Random History. 27 February 2008. Retrieved 2010-05-0 18. "The History of Cancer". American Cancer Society. 25 March 2002. Retrieved 200610-09. 19. . lson, James Stuart (2002). Bathsheba's breast: women, cancer & history. Baltimore: The Johns Hopkins University Press. pp. 913. ISBN 0-8018 -6936-6. 20. Pike M, Spicer D, Dahmoush L, Press M. Estrogens, progesterones, normal breast cell proliferation and breast cancer risk. Epidemiol Rev. 1993;15:17.
21. . Petit T, Dufour P, Tannock I (June 2011). "A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer". Endocr. Relat. Cancer 18 (3): R7989. doi:10.1530/ERC10-0162. PMID 21502311. 22. . Lee, I-Min; Shiroma, Eric J; Lobelo, Felipe; Puska, Pekka; Blair, Steven N; Katzmarzyk, Peter T (1 July 2012). "Effect of physical inactivity on major non- communicable diseases worldwide: an analysis of burden of disease and life expectancy". The Lancet 380 (9838): 21929. doi:10.1016/S01406736(12)610319. PMID 22818936
23. Russo J, Russo I (1980). "Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence". Am J Pathol 100 (2): 505 506. PMC1903536. PMID 6773421. "In contrast, abortion is associated with increased risk of carcinomas of the breast. The explanation for these is not known, but the parallelism between the DMBAcarcinoma model and the human situation is striking. interrupt this process, leaving in in the rat the gland
undifferentiated structures
mammary
carcinogenesis."
24. . Gobbi H, Dupont W, Simpson JF, et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst. 1999;91:2096. 25. Shapira D, Urban N. A minimalist policy for breast cancer Surveillance. JAMA. 1991;265:380382.
26. Smith R, von Eschenbach A, Wender R, et al. American Cancer Society Guidelines for the early detection of cancer. CACancer J. Clin. 2001;51:38 75. 27. Veljkovi M, Veljkovi, S (Sep 2010). "[The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users].". Medicinski pregled 63 (910): 657 61.PMID 21446095. 28. Woods E, Helvie M, Ikeda D, et al. Solitary breast papilloma: comparison of mammographic, galacytographic, and pathologic findings. Am J Roentgenol. 1992;159:487 29. Watson M (2008). "Assessment of suspected cancer". InnoAiT 1 (2): 94107. . 30.Kahlenborn C, Modugno, F, Potter, DM, Severs, WB (Oct 2006). "Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-an alysis.". Mayo Clinic proceedings. Mayo Clinic 81 (10): 1290302. doi:10.4065/81.10.1290 PMID 17036554. 31.Kahlenborn C, Modugno, F, Potter, DM, Severs, WB (Oct 2006). "Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.". Mayo Clinic proceedings. Mayo Clinic 81 (10): 1290302. 32.McKay M, Langlands A. Prognostic Factors inBreast Cancer (Letter). N Engl J Med. 1992:327: 13171318. 33.Malone KE, Daling JR, Thompson JD, OBrien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population: analysis in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998;279:922929. 34.Merck Manual of Diagnosis and Therapy (February 2003). "Breast Disorders: Breast Cancer". Retrieved 2008-02-05.
35.Medicine(23 August, 2006)."Breast Cancer Evaluation". Retrieved 2008-02-05. 36.Massarut S, Baldassare G, Belleti B, Reccanello S, D'Andrea S, Ezio C, Perin T, Roncadin M, Vaidya JS (2006). "Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid". J Clin Oncol 24 (18S): 10611. 36. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancerA multicenter study. N Engl J Med. 1998;339:941. 37. Yang, L; Jacobsen, KH (December 2008). "A systematic review of the association between breastfeeding and breast cancer.". Journal of women's health (2002) 17 (10): 163545. doi:10.1089/jwh.2008.0917. PMID 1904935 38.Yalom, Marilyn (1997). A history of the breast. New York: Alfred A. Knopf. p. 234. ISBN 0-679-43459-3. 39.Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thrlimann B, Senn HJ (August 2009). "Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009". Ann. Oncol. 20 (8): 131929. doi:10.1093/annonc/mdp322. PMC 2720818. PMID 19535820. 40. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thrlimann B, Senn HJ (August 2009). "Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009". Ann. Oncol. 20 (8): 131929. doi:10.1093/annonc/mdp322. PMC 2720818. PMID 19535820.